Endometrial mullerian adenosarcoma after toremifene treatment in breast cancer patients: a case report / 부인종양
Journal of Gynecologic Oncology
; : 269-272, 2010.
Article
Dans En
| WPRIM
| ID: wpr-6889
Responsable en Bibliothèque :
WPRO
ABSTRACT
Toremifene is an anti-estrogen which has been shown to be effective in the treatment of breast cancer, and is thought to be a less uterotrophic agent than tamoxifen. The risk assessment concerning endometrial cancer has been inconclusive because of its rare use up to the mid-1990s. We report a case of an adenosarcoma, which is a very rare type of uterine malignancy, after toremifene treatment for 5 years in a breast cancer patient. After 1 year of toremifene use, the patient had a benign Mullerian adenofibroma. After an additional 4 years of toremifene treatment, the endometrial polypoid lesion was transformed into a Mullerian adenosarcoma. Although toremifene is a promising anti-estrogenic agent in the treatment of breast cancer patients, clinicians should not neglect the possibility of a uterine malignancy.
Texte intégral:
1
Indice:
WPRIM
Sujet Principal:
Tamoxifène
/
Région mammaire
/
Tumeurs du sein
/
Adénofibrome
/
Tumeurs de l'endomètre
/
Torémifène
/
Adénosarcome
/
Appréciation des risques
Type d'étude:
Etiology_studies
/
Risk_factors_studies
Limites du sujet:
Female
/
Humans
langue:
En
Texte intégral:
Journal of Gynecologic Oncology
Année:
2010
Type:
Article